A detailed history of Aqr Capital Management LLC transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Aqr Capital Management LLC holds 261,964 shares of ADPT stock, worth $1.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
261,964
Previous 182,076 43.88%
Holding current value
$1.49 Million
Previous $659,000 103.49%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.37 - $5.12 $269,222 - $409,026
79,888 Added 43.88%
261,964 $1.34 Million
Q2 2024

Aug 14, 2024

BUY
$2.34 - $3.96 $302,330 - $511,635
129,201 Added 244.35%
182,076 $659,000
Q1 2024

May 15, 2024

BUY
$2.88 - $4.8 $38,448 - $64,080
13,350 Added 33.78%
52,875 $169,000
Q4 2023

Feb 14, 2024

BUY
$3.46 - $5.33 $91,042 - $140,248
26,313 Added 199.16%
39,525 $193,000
Q3 2023

Nov 14, 2023

SELL
$5.07 - $8.44 $63,116 - $105,069
-12,449 Reduced 48.51%
13,212 $72,000
Q2 2023

Aug 14, 2023

SELL
$6.19 - $8.78 $98,804 - $140,146
-15,962 Reduced 38.35%
25,661 $172,000
Q1 2023

May 15, 2023

SELL
$7.8 - $10.11 $224,593 - $291,107
-28,794 Reduced 40.89%
41,623 $367,000
Q4 2022

Feb 14, 2023

BUY
$6.26 - $9.34 $193,158 - $288,195
30,856 Added 78.0%
70,417 $537,000
Q3 2022

Nov 14, 2022

SELL
$6.5 - $12.67 $314,008 - $612,075
-48,309 Reduced 54.98%
39,561 $282,000
Q2 2022

Aug 15, 2022

SELL
$6.4 - $14.73 $482,688 - $1.11 Million
-75,420 Reduced 46.19%
87,870 $688,000
Q1 2022

May 16, 2022

BUY
$10.12 - $28.9 $1.65 Million - $4.72 Million
163,290 New
163,290 $2.27 Million
Q2 2021

Aug 16, 2021

SELL
$32.22 - $44.59 $603,190 - $834,769
-18,721 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$37.26 - $67.74 $697,544 - $1.27 Million
18,721 New
18,721 $734,000

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $812M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.